80
Views
3
CrossRef citations to date
0
Altmetric
Review

The freedom to tinker: patent law and experimental use

Pages 167-200 | Published online: 22 Apr 2005

Bibliography

  • AUSTRALIAN LAW REFORM COMMISSION: Genes and ingenuity: gene patenting and human health. Report 99. Australian Commonwealth, Sydney (June 2004):64.
  • BURK D, LEMLEY M: Is patent law technology-specific? Berkeley TechnoL Law J. (2002) 17:1155.
  • JANIS M: Experimental use and the shape of patent rights for plant innovation, economics of innovation and science policy. Department of Economics, Iowa State University (2003).
  • Monsanto v Stauffer Chemical Co. (UK) (1985) RPC 515.
  • Monsanto Co. v Stauffer Chemical Co. (NZ) (1984) FSR 559.
  • Monsanto v Stauffer (1987) FSR 57.
  • Monsanto v Stauffer Japan (1989) 20 IIC 91.
  • CORNISH W, LLEWELYN D: Intellectual Property: Patents, Copyright, Ttrade Marks and Allied Rights. Sweet and Maxwell, London (2003):246–247.
  • LENTZ E: Pharmaceutical and biotechnology research after Integra and Madey. Biotech. Law Rep. (2004) 23:265.
  • Roche Products, Inc. v Bolar Pharmaceuticals Co., Inc. (1984) 733 F. 2d 858.
  • Iainische Versuche I (Interferon Gamma) (1997) RPC 623 at 642–643.
  • Iainische Versuche II (Erythropoietin) (1998) RPC 423.
  • MCSHERRY C: Who Owns Academic Work?: Battling for Control of Intellectual Property. Harvard University Press, Harvard (2001).
  • PERELMAN M: Steal This Idea: Intellectual Property Rights and the Corporate Confiscation of Creativity Palgrave, New York (2002).
  • MONOTTI A, RICKETSON S: Universities and Intellectual Property: Ownership and Exploitation. Oxford University Press, Oxford (2003).
  • PERELMAN M. Steal This Idea: Intellectual Property Rights and the Corporate Confiscation of Creativity Palgrave, New York (2002):88.
  • LIEBERWITZ R: The marketing of higher education. Cornell Law Rev. (2004) 89:763.
  • ARMSTRONG J: Bayh-Dole under siege: the challenge to federal patent policy as a result of Madey v Duke University. J. Coll. Univ. Law (2004) 30(3):619.
  • QUIGLEY T: Commercialization of the state university: why the intellectual property restoration act of 2003 is necessary. Univ. Pennsylvania Law Rev. (2004) 152:2001.
  • EPSTEIN R: Steady the course: propertyrights in genetic material. In: Perspectives on Properties of the Human Genome Project. Kieff FS (Ed.), Academic Press, Elsevier, Amsterdam (2003):159.
  • LLEWELYN M: Perspectives on patenting biological material. In: Industrial Property in the Bio-Medical Age: Challenges for Asia. The Hague: Kluwer Law International. (2003):73 at 96, f. 63.
  • RESNIK D: Patents and the research exemption. Science (2003) 299:821.
  • LONG C: Information costs in patent and copyright. Virginia Law Rev. (2004) 90:465.
  • RESNIK D: Discoveries, inventions and gene patents. In: Who Owns Life? Magnus D, Caplan A, McGee G (Eds), Prometheus Books, New York (2002):135.
  • ARMSTRONG J: Bayh-Dole under siege: the challenge to federal patent policy as a result of Madey v Duke University. J. Coll. Univ. Law (2004) 30(3):619 at 637.
  • JOHNSON J: The experimental use exception in Japan: A model for US patent law. Pacific Rim Law Policy J. (2003) 12(2):499.
  • DERZKO N: A local and comparative analysis of the experimental use exception - is harmonization appropriate? J. Law Tech. (2003) 44:1.
  • MUELLER J: No 'dilettante affair': rethinking the experimental use exception to patent infringement for biomedical research tools. Washington Law Rev. (2001) 76:41–42.
  • MUELLER J: The evanescent experimental use exemption from US patent infringement liability: implications for university/nonprofit research and development. Baylor Law Rev. (2004) 56:forthcoming.
  • Whittemore v Cutter (1813) 29 F. Cas. 1120.
  • Sawin v Guild (1813) 21 Fed. Cas. 554.
  • Chesterfield v United States (1958) 159 F.Supp. 371
  • Ruth v Stearns-Roger Manufacturing Co. (1935) 13 F.Supp. 697.
  • Folsom v Marsh (1841) 9 Fed. Cas. 342.
  • Roche Products, Inc. v Bolar Pharmaceuticals Co., Inc. (1984) 733 F. 2d 858.
  • Madey v Duke University (2002) 307 F.3d 1351.
  • Integra Lifesciences Ltd v Merck KgaA (2003) 331 F. 3d 860.
  • App/era v M Research, Inc. (2004) 311 F. Supp. 2d 293.
  • FEDERAL TRADE COMMISSION: To promote innovation: the proper balance of competition and patent law and policy, a report by the Federal Trade Commission (October 2003):37.
  • Roche Products, Inc. v Bolar Pharmaceuticals Co., Inc. (1984) 733 F. 2d 858.
  • Roche Products, Inc. v Bolar Pharmaceuticals Co., Inc. (1984) 733 F. 2d 858 at 863.
  • Bolar Pharmaceutical Co., Inc. v Roche Products, Inc. (1984) 469 U.S. 856.
  • 35 USC 271 (e)(1).
  • Eli Lilly & Co v Medtronic (1990) 496 US 661.
  • Infigen v Advanced Cell Technology (1999) 65 F.Supp.2d 967.
  • Infigen v Advanced Cell Technology (1999) 65 F.Supp.2d at 981.
  • Embrerc, Inc. v. Service Engineering Corp. (2000) 216 F.3d 1343.
  • Embrerc, Inc. v. Service Engineering Corp. (2000) 216 F.3d 1353.
  • EISENBERG R: Patent swords and shields. Science (2003) 299:1018–1019.
  • BRICKLEY P: Patent rights wrangle puts law in question. Scientist (2003) 17(42).
  • Madey v Duke University (2001) 266 F. Supp. 2d 420.
  • Madey v Duke University (2001) 266 F. Supp. 2d 425.
  • Madey v Duke University (22 October 2001). Appellant's Opening Brief.
  • Madey v Duke University (2002) 307 F.3d 1351.
  • Madey v Duke University (2002) 307 F.3d 1362.
  • Madey v Duke University (2002) 307 F.3d 1362–1363.
  • Madey v Duke University (2002) 307 F.3d 1363.
  • Duke University v Madey. Supreme Court of the United States. Consumer Project on Technology and Public Knowledge et al. Petition for a writ of certiorari (January 2003).
  • Duke University v Madey, Supreme Court of the United States. Brief for the Association of American Medical Colleges et al. Petition for a writ of certiorari (January 2003).
  • Duke University v Madey. Supreme Court of the United States. Brief for the Association of American Medical Colleges et al. Petition for a writ of certiorari (January 2003):3.
  • RIMMER M: The attack of the clones: patent law and stem cell research. J. Law Med. (2003) 10(4):488–505.
  • WYSOCKI B: Cutting edge: a laser case sears universities right to ignore patents. Wall St. J. (2004) :A1.
  • DONLEY B: Using patented materials in your research: what you should know. Wisconsin Alumni Res. Fdn (21 May 2003).
  • Duke University v Madey, Supreme Court of the United States. Brief for the United States as Amicus Curiae. Petition for a writ of certiorari (May 2003).
  • Duke University v Madey, Supreme Court of the United States. Brief for the United States as Amicus Curiae. Petition for a writ of certiorari (May 2003):5.
  • Duke University v Madey. Supreme Court of the United States. Brief for the United States as Amicus Curiae. Petition for a writ of certiorari (May 2003):16.
  • Madey v Duke University (2004) WL 2148935.
  • Madey v Duke University (2004) WL 2148935:8.
  • Madey v Duke University (2004) WL 2148935:10.
  • DUKE UNIVERSITY: Duke University statement on supreme court action in case involving academic research (27 May 2003).
  • JANIS M: Experimental use and the shape of patent rights for plant innovation, economics of innovation and science policy. Department of Economics, Iowa State University (2003):5.
  • Integra Lifesciences Ltd v Merck KgaA (2003) 331 F. 3d860.
  • Integra Lifesciences Ltd v Merck KgaA 1999 WL 398180.
  • Integra Lifesciences Ltd v Merck KgaA (2003)331 F. 3d860 at 864.
  • Integra Lifesciences Ltd v Merck KgaA (2003)331 F. 3d 860 at 872.
  • Integra Lifesciences Ltd v Merck KgaA (2003) 331 F. 3d 860 at 875.
  • Integra Lifesciences Ltd v Merck KgaA (2003) 331 F. 3d 860 at 876.
  • Integra Lifesciences Ltd v Merck KgaA (2003) 331 F. 3d 860 at 873.
  • SAMPSON T: Madey, Integra and the wealth of nations. Eur. Intellect. Prop. Rev. (2004) 26(1):1–6.
  • Merck KgaA v Integra Lifesciences I, Ltd. Brief of Amicus Curiae Wyeth in support of the petitioner. (2004) WL 741062.
  • Merck KgaA v Integra Lifesciences I, Ltd. Brief in Opposition of Integra Lifesciences I, Ltd. (2004) WL 741062.
  • Appiera v MI Research, Inc. (2004) 311 F. Supp. 2d 293.
  • Madey v Duke University (2002) 307 F.3d 1351.
  • App/era v MI Research, Inc. (2004) 311 F. Supp. 2d 293 at 297.
  • Appiera v MI Research, Inc. (2004) 311 F. Supp. 2d 293 at 296.
  • MJ RESEARCH: MJ Research, Inc. responds to Applera press release regarding patent-antitrust suit. Press Release, Waltham and Watertown Massachusetts (22 April 2004).
  • Soitec S.A. v Silicon Genesis Corporation (2003) 81 Fed. Appx. 724.
  • Soitec S.A. v Silicon Genesis Corporation (2003) 81 Fed. Appx. 724 at 3.
  • WYSOCKI B: Cutting edge: a laser case sears universities' right to ignore patents. Wall St. J. (11 October 2004):A1.
  • FEDERAL TRADE COMMISSION: To promote innovation: the proper balance of competition and patent law and policy, a report by the Federal Trade Commission (October 2003):37.
  • ARMSTRONG J: Bayh-Dole under siege: the challenge to federal patent policy as a result of Madey v Duke University. J. College Univ. Law (2004) 30(3):619 at 635.
  • EISENBERG R: Patent swords and shields. Science (2003) 299:1018–1019.
  • SAMPSON T: Madey, Integra and the wealth of nations. Eur. Intellect. Prop. Rev. (2004) 26(1):1–6.
  • Whittemore v Cutter (1813) 29 F. Cas 1120.
  • SAMPSON T: Madey, Integra and the wealth of nations. Eur. Intellect. Prop. Rev. (2004) 26(1):1.
  • SAMPSON T: Madey, Integra and the wealth of nations. Eur. Intellect. Prop. Rev. (2004) 26(1):6.
  • GITTER D: International conflicts over patenting human DNA sequences in the United States and the European Union: an argument for compulsory licensing and a fair use exemption. New York Univ. Law Rev. (2001) 76:1623.
  • CAHOY D: Oasis or mirage: efficient breach as a relief to the burden of contractual recapture of patent and copyright limitations. Harvard J. Law Tech. (Fall 2003):135.
  • VAVER D: Canada's intellectual property framework: a comparative overview. Intellect. Prop. J. (2003–2004) 17:125.
  • Micro-Chemicals Ltd. v Smith lane and French Inter-American Ltd (1971) 25 D.L.R. 79.
  • JANIS M: Experimental use and the shape of patent rights for plant innovation, economics of innovation and science policy. Department of Economics, Iowa State University (2003):3.
  • JANIS M: Experimental use and the shape of patent rights for plant innovation, economics of innovation and science policy. Department of Economics, Iowa State University (2003):6.
  • JANIS M: Experimental use and the shape of patent rights for plant innovation, economics of innovation and science policy. Department of Economics, Iowa State University (2003):12.
  • JANIS M: Experimental use and the shape of patent rights for plant innovation, economics of innovation and science policy. Department of Economics, Iowa State University (2003):7.
  • RESNIK D: Patents and the research exemption. Science (2003) 299:821.
  • CAI M: Madey v Duke University: Shattering the myth of universities' experimental use defense. Berkeley Tech. Law J. (2004) 19:175.
  • DERZKO N: A local and comparative analysis of the experimental use exception - is harmonization appropriate? J. Law Tech. (2003) 44:1.
  • EPSTEIN R: Steady the course: property rights in genetic material. In: Perspectives on Properties of the Human Genome Project. Kieff FS (Ed), Academic Press, Elsevier, Amsterdam. (2003):159.
  • DREYFUSS RC: Varying the course in patenting genetic material: a counter-proposal to Richard Epstein's steady course. In: Perspectives on Properties of the Human Genome Project. Kieff FS (Ed.), Academic Press, Elsevier, Amsterdam (2003):195.
  • DREYFUSS RC: Protecting the public domain of science: has the time for an experimental use defense arrived? Arizona Law Rev. (2004) 46:457.
  • NICOL D, NIELSEN J: Submission to the Advisory Council on Intellectual Property: patents and experimental use. Centre for Law and Genetics, the University of Tasmania (April 2004).
  • WENGER H: The Post-Madey Research Exemption, Foley and Lardner: Attorneys at Law (2003).
  • Muntz v Foster (1844) 2 WPC 96.
  • Frearson v Loe (1878) 9 Ch. D.48.
  • Frearson v Loe (1878) 9 Ch. D. 48 at 66.
  • Molins and Molins Machine Co Ltd v Industrial Machine Co. Ltd (1937) 54 RPC 94.
  • Blanco White's Patents for Inventions, 4th Ed. (1974) paragraph 3–216.
  • Netherlands v European Parliament (C377/98), 2001 WL 758973, (2001) ECR 1–7079, Celex No. 698C0377, EU : Case C-377/98, ECJ (14 June, 2001).
  • CORNISH W, LLEWELYN D: Intellectual Property: Patents, Copyright, Trade Marks and Allied Rights. Sweet and Maxwell, London (2003):244–245.
  • Monsanto v Stauffer Chemical Co. (UK) (1985) RPC 515.
  • Monsanto v Stauffer Chemical Co. (UK) (1985) RPC 515 at 522.
  • Micro-Chemicals Ltd. v Smith Kline and French Inter-American Ltd (1971) 25 DLR 79.
  • Monsanto v Stauffer Chemical Co. (UK) (1985) RPC 515 at 538.
  • Monsanto v Stauffer Chemical Co. (UK) (1985) RPC 515 at 542.
  • Monsanto Co. v Stauffer Chemical Co. (NZ) (1984) FSR 559.
  • Monsanto v Stauffer (1988) FSR 57
  • Monsanto v Stauffer Japan (1989) 20 IIC 91.
  • Smith Kline & French Laboratories Ltd v Evans Medical Ltd (1989) F.S.R. 513.
  • Smith Kline & French Laboratories Ltd v Evans Medical Ltd (1989) F.S.R. at 523.
  • Smith Kline & French Laboratories Ltd v Evans Medical Ltd (1989) F.S.R. at 523–524.
  • Smith Kline & French Laboratories Ltd v Evans Medical Ltd (1989) F.S.R. at 524.
  • Auchincloss v Agricultural & Veterinary Supplies Ltd (1997) R.P.C. 649; on appeal (1999) R.P.C. 397.
  • Auchincloss v Agricultural & Veterinary Supplies Ltd (1997) R.P.C. 649 at 682.
  • Auchincloss v Agricultural & Veterinary Supplies Ltd (1999) R.P.C. 397 at 405.
  • Inhale Therapeutic Systems v Quadrant Healthcare Plc (2002) RPC 21.
  • Inhale Therapeutic Systems v Quadrant Healthcare Plc (2002) RPC 21 at 145.
  • Kirin-Amgen Inc. v Transkaryotic Therapies, Inc. (No. 2) (2002) RPC 3.
  • BINNS R, DRISCOLL B: Are the generic companies winning the battle? Managing Intellectual Property (1999) 86:36.
  • ICl/Pharbia and Medicopharma (Atenolol) (1993) NJ 735 (1993) GRUR Int. 887 (Dutch Supreme Court).
  • Applied Research Systems/Organon (Follicle-Stimulating Hormone) (1996) NJ 463,28 IIC 558 (1997)
  • DUTCH SUPREME COURT: Affirming a more extensive judgement of The Hague Court of Appeal, 29 IIC 702 (1998).
  • Kirian Amgen/Boehringer Mannheim (Erythropoietin), Judgment of February 3, 1994 (docket No. 93/960).
  • THE HAGUE COURT OF APPEAL: Affirmed on other grounds by the Dutch Supreme Court: (1996) NJ 462.
  • Generics BV v Smith Kline & French Laboratories Ltd (1997) R.P.C. 801, 803 (European Ct. of J. 1997).
  • Wellcome Foundation v Parexel International & Flamel, Tribunal de Grande Instance de Paris, 20th February 2001.
  • ER Squibb & Sons, Inc. v Giovannia Aguggini (12 June 1995) T Milano.
  • Ethofumesate (1990) GRUR 997.
  • Klinische Versuche I (Interferon Gamma) (1997) RPC 623.
  • Klinische Versuche I (Interferon Gamma) (1997) RPC 623 at 637.
  • Klinische Versuche I (Interferon Gamma) (1997) RPC 623 at 638.
  • Klinische Versuche I (Interferon Gamma) (1997) RPC 623 at 639.
  • Klinische Versuche I (Interferon Gamma) (1997) RPC 623 at 642–643.
  • Klinische Versuche II (Erythropoietin) (1998) RPC 423.
  • Klinische Versuche II (Erythropoietin) (1998) RPC 423 at 432–433.
  • Klinische Versuche II (Erythropoietin) (1998) RPC 423 at 436.
  • Klinische Versuche II (Erythropoietin) (1998) RPC 423 at 433–434.
  • Klinische Versuche II (Erythropoietin) (1998) RPC 423 at 437.
  • Klinische Versuche II (Erythropoietin) (1998) RPC 423 423 at 437–438.
  • Klinische Versuche I (Interferon Gamma) 2001 GRUR 43; 1 ByR 1864/95 [German].
  • GODDARD H: The Experimental Use Exception: A European Perspective. Centre for Advanced Studies and Research on Intellectual Property, University of Washington, Seattle (2002):7.
  • CORNISH W: Experimental Use of Patented Inventions in European Community States, IIC (1998) 29(7):735.
  • STOATE N: EU Enlargement, the Bolar Exemption and Parallel Imports. Bioscience Law Rev. (13 October 2003).
  • L'ECLUSE P, LONGEVAL C: The Bolar clause in the new European pharmaceutical regulatory package. Practical Law (1 June 2004).
  • THE ROYAL SOCIETY: Keeping science open: the effects of intellectual property policy on the conduct of science. The Royal Society, London (April 2003).
  • THE ROYAL SOCIETY: Keeping science open: the effects of intellectual property policy on the conduct of science. The Royal Society, London (April 2003):11.
  • THE NUFFIELD COUNCIL ON BIOETHICS: The ethics of patenting DNA: A discussion paper. The Nuffield Council on Bioethics, London (2002).
  • THE NUFFIELD COUNCIL ON BIOETHICS: The ethics of patenting DNA: A discussion paper. The Nuffield Council on Bioethics, London (2002):60–61.
  • CORNISH W, LLEWELYN M, ADCOCK M: Intellectual property rights and genetics: a study into the impact and management of intellectual property rights within the healthcare sector. Public Health Genetics Unit, Cambridge (2003).
  • CORNISH W, LLEWELYN M, ADCOCK M: Intellectual property rights and genetics: a study into the impact and management of intellectual property rights within the healthcare sector. Public Health Genetics Unit, Cambridge (2003):25–26.
  • CORNISH W, LLEWELYN M, ADCOCK M: Intellectual property rights and genetics: a study into the impact and management of intellectual property rights within the healthcare sector. Public Health Genetics Unit, Cambridge (2003):26.
  • CORNISH W, LLEWELYN M, ADCOCK M: Intellectual property rights and genetics: a study into the impact and management of intellectual property rights within the healthcare sector. Public Health Genetics Unit, Cambridge (2003):27.
  • CORNISH W, LLEWELYN M, ADCOCK M: Intellectual property rights and genetics: a study into the impact and management of intellectual property rights within the healthcare sector. Public Health Genetics Unit, Cambridge (2003):148–149.
  • Frearson v Loe (1876) 9 ChD 48.
  • Patents Act 1990 (Cth) ss 9(a), 18(1)(d).
  • SMITH C: Experimental use exception to patent infringement: where does Australia stand? Intellectual Property Forum (2003) 53:14,15.
  • NICOL D, NIELSEN J: Patents and medical biotechnology: an empirical analysis of issues facing the Australian industry. Centre for Law and Genetics occasional paper (2003) 6.
  • NICOL D, NIELSEN J: Patents and medical biotechnology: an empirical analysis of issues facing the Australian industry. Centre for Law and Genetics occasional paper (2003) 6:218.
  • OPESKIN B: Inventions, Patents, and Research, ACIPA Symposium (19 March 2004).
  • AUSTRALIAN LAW REFORM COMMISSION: Gene patenting and human health: 27. Australian Commonwealth, Sydney (July 2003).
  • AUSTRALIAN LAW REFORM COMMISSION: Gene patenting and human health: discussion paper 68. Australian Commonwealth, Sydney (February 2004).
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and ingenuity: gene patenting and human health: report 99. Australian Commonwealth, Sydney (June 2004).
  • ADVISORY COUNCIL ON INTELLECTUAL PROPERTY: Patents and experimental use: issues paper. Commonwealth Government, Canberra (February 2004).
  • ADVISORY COUNCIL ON INTELLECTUAL PROPERTY: Patents and experimental use: options paper. Commonwealth Government, Canberra (December 2004).
  • GENETIC TECHNOLOGIES LTD: Genetic Technologies and Myriad Genetics announce strategic licensing agreement (28 October 2002).
  • GENETIC TECHNOLOGIES LTD: Letter from GTG to Medical and Scientific Colleagues (21 July 2003).
  • Genetic Technologies Limited: Issued Licenses (29 September 2004)
  • GENETIC TECHNOLOGIES LTD: GTG reports significant licensing agreement with Genzyme Corp. of USA (22 September 2004).
  • HOLMES J: Patently a problem. Four corners, ABC (11 August, 2003).
  • CANTOR C: A patent's place. Bio-IT World (13 August, 2003).
  • Genetic Technologies Ltd v Applera Corporation. United States District Court, Northern District of California, San Francisco Division, No. c-03-1316 PJH (2003).
  • APPLERA CORP.: Opening brief in Genetic Technologies Limited v Appkra Coloration. United States District Court, Northern District of California, San Francisco Division, No. c-03-1316 PJH (2003).
  • SMITH D: DNA scientists happy to buy junk. The Sydney Morning Herald (4 August 2003).
  • HOLMES J: Interview with Dr Mervyn Jacobson. Four Corners, ABC (4 August 2003).
  • GORMAN P: NZ health boards in patent dispute. The Christchurch Press (21 August, 2004):3.
  • Legal Action Against GTG. The Christchurch Press (19 August, 2004).
  • O'NEILL G: NZ health service takes on GTG over licence fees. Australian Biotechnology News (24 August, 2004).
  • OFFICES OF THE MINISTER OF HEALTH AND ASSOCIATE MINISTER OF COMMERCE: Implications of the granting of patents over genetic material. Cabinet Policy Committee. (November 2003).
  • OFFICES OF THE MINISTER OF HEALTH AND ASSOCIATE MINISTER OF COMMERCE: Memorandum to Cabinet Policy Committee: report back with recommendations and options for addressing genetic material patents (June 2004).
  • SMITH HUGHES S: Making dollars out of DNA: the first major project in biotechnology and the commercialization of molecular biology, 1974-1980. Isis (2001) 92:541–578.
  • RABINOW P: Making PCR: a story of biotechnology. The University of Chicago Press, Chicago (1996).
  • COLLINS F: A patent's place. Bio-IT World (13 August 2003).
  • HOLMES J: Interview with Professor Francis Collins. Four Corners, ABC (9 July 2003).
  • COLLINS F: A patent's place. Bio-IT World (13 August 2003).
  • NATIONAL INSTITUTES OF HEALTH: NIH principles and guidelines for sharing of biomedical research resources (25 May 1999).
  • AUSTRALIAN LAW REFORM COMMISSION: genes and ingenuity: gene patenting and human health. Report 99. Australian Commonwealth, Sydney (June 2004):12.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and ingenuity: gene patenting and human health. Report 99. Australian Commonwealth, Sydney. (June 2004):336.
  • ELKMAN S: The Research Exemption to Patent Infringement: a doctrine in search of a principle. Intellectual Property Research Institute of Australia. Working Paper No. 10/04 (September 2004).
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and Ingenuity: gene patenting and human health. Report 99. Australian Commonwealth, Sydney (June 2004):327–328.
  • SMITH C: Experimental use exception to patent infringement: where does Australia stand? Intellectual Property Forum (2003) 53:14,15.
  • Madey v Duke University (2002) 307 F.3d 1351.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and Ingenuity: Gene Patenting and Human Health. Report 99. Australian Commonwealth, Sydney (June 2004):12.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and Ingenuity: Gene Patenting and Human Health. Report 99. Australian Commonwealth, Sydney (June 2004):329.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and Ingenuity: Gene Patenting and Human Health. Report 99. Australian Commonwealth, Sydney (June 2004):330.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and Ingenuity: Gene Patenting and Human Health. Report 99. Australian Commonwealth, Sydney (June 2004):340.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and Ingenuity: Gene Patenting and Human Health. Report 99. Australian Commonwealth, Sydney (June 2004):388.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and Ingenuity: Gene Patenting and Human Health. Report 99. Australian Commonwealth, Sydney (June 2004):337–338.
  • WATERHOUSE D: Plant breeder's rights and experimental use. ACIPA Symposium (19 March 2004).
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and ingenuity: gene patenting and human health. Report 99. Australian Commonwealth, Sydney (June 2004):325.
  • Grain Pool Of Western Australia v Commonwealth (2000) 46 IPR 515.
  • RIMMER M: Franklin Barley: patent law and plant breeders rights. Murdoch Univ. Electronic J. Law (2003) 10:4.
  • AUSTRALIAN LAW REFORM COMMISSION: Gene patenting and human health: Issues Paper 27. Australian Commonwealth, Sydney (July 2003):223.
  • New York University v Nissin Molecular Biology Institute Inc. (1994) 29 IPR 173.
  • Monsanto Company v Stauffer Chemical Company (NZ) (1984) FSR 559.
  • New York University v Nissin Molecular Biology Institute Inc. (1994) 29 IPR 173.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and ingenuity: gene patenting and human health. Report 99. Australian Commonwealth, Sydney. (June 2004):339.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and ingenuity: gene patenting and human health. Report 99. Australian Commonwealth, Sydney. (June 2004):342.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and ingenuity: gene patenting and human health. Report 99. Australian Commonwealth, Sydney. (June 2004):343.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and ingenuity: gene patenting and human health. Report 99. Australian Commonwealth, Sydney. (June 2004):343–344.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and ingenuity: gene patenting and human health. Report 99. Australian Commonwealth, Sydney. (June 2004):344.
  • AUSTRALIAN LAW REFORM COMMISSION: Genes and ingenuity: gene patenting and human health. Report 99. Australian Commonwealth, Sydney. (June 2004):344–345.
  • ADVISORY COUNCIL ON INTELLECTUAL PROPERTY: Patents and experimental use: issues paper. Commonwealth Government, Canberra (February 2004).
  • Agreement on Trade-Related Aspects of Intellectual Property Rights (Annex 1C of the Marrakesh Agreement Establishing the World Trade Organization), (1995) ATS 8, (1 January 1995).
  • CANADA: Patent protection of pharmaceutical products: Complaint by the European communities and their member states (17 March 2000) WT/DS114/R.
  • CANADA: Patent protection of pharmaceutical products: Complaint by the European communities and their member states (17 March 2000) WT/DS114/R:29.
  • CANADA: Patent protection of pharmaceutical products: Complaint by the European communities and their member states (17 March 2000) WT /DS114/R: 55–56.
  • CANADA: Patent protection of pharmaceutical products: Complaint by the European communities and their member states (17 March 2000) WT/DS114/R:98.
  • Patents Act 1977 (UK) s 60(5)(6).
  • Council Agreement relating to Community Patents No 89/695/EEC, 15 December 1989, OJ L401/01 art 27(6).
  • JOINT STANDING COMMITTEE ON TREATIES: The Australia - United States Free Trade Agreement: report 61. Australian Parliament, Canberra (June 2004)
  • THE SENATE: Select committee on the Free Trade Agreement between Australia and the United States of America. Canberra: Australian Parliament (August 2004).
  • FAUNCE T: Senate Select Committee on the Free Trade Agreement between Australia and the United States of America. Parliament House, Canberra (21 June 2004):6.
  • HEATH I: Recent developments in protecting and commercialising intellectual property (10 August 2004).
  • DRAHOS P, LOKUGE B, FAUNCE T, GODDARD M, HENRY D: Pharmaceuticals, intellectual property and free trade: the case of the US - Australia Free Trade Agreement. Prometheus (September 2004) 22(3):243.
  • WESCHLER C: The informal experimental use exception: university research after Madey v Duke University. New York Univ. Law Rev. (2004) 76:1536.
  • JANIS M: Experimental use and the shape of patent rights for plant innovation. Economics of Innovation and Science Policy, Department of Economics, Iowa State University, (2003):6.
  • CORNISH W: Experimental use of patented inventions in European community states. IIC (1998) 29(7):735.
  • MCKEOUGH J, STEWART A. GRIFFITH P: Intellectual property in Australia, 3rd Ed. Butterworths, Sydney. (2004):12.
  • OECD: Patents and innovation: trends and policy challenges. OECD, Paris. (2003):23.
  • LLEWELYN M: Perspectives on patenting biological material. In: Industrial Property in the Bio-Medical Age: Challenges for Asia. Heath C, Sanders AK (Eds). Kluwer Law International (2003):73.
  • http://www.freedorn_to_tinker.com/
  • http://www.austlii.edu.au/au/other/alrc/publi cations/reports/99/
  • http://www.econdastate.edu/department/sem inadispw/Janis-seminar-Fall-03.pdf
  • http://www.ftc.gov/os/ 192003/10/innovationrp t. pdf
  • http: //www. the- scientist . com/yr 192003/mar/prof2_030310.ht ml
  • http://jurist.law.pittedu/amicus/duke_v_ma dey_cert_petition_au.pdf
  • http://www.aamc.org/newsroom/pressrel/pat entbrief.pdf
  • http://www.usdojgov/osg/briefs/ 192002/2pet/6 invit/2002-1007.pet.ami. inv.html
  • http://www.ecomiastate.edu/department/sem inar/ispw/Janis-seminar-Fall-03. pdf
  • http://www.ftc.gov/os/ 192003/10/innovationrp t. pdf
  • http://www.acip.gov.au/expusesubs/NicoP/02 060/020Nielsen,°/020Uni%20ofb/020Tas.pdf
  • http://www.bundesverfassungsgericht.de/cgi-bin/link.pl?entscheidungen
  • http://www.law.washington.edu/casrip/Symp osium/Number7/1-Goddar.pdf
  • http: //www. royalsoc.ac.uk/displaypagedoc.as p?id6343
  • http://www.nuffieldbioethics.org/go/ourwork /patentingdna/publication_310.html
  • http://www.phgu.org.uk/about_phgufintellec t_prop_rights.html
  • http://www.austlii.edu.au/au/other/alrc/publi cations/issues/27/
  • http://www.austlii.edu.au/au/other/alrc/publi cations/dp/68/
  • http://www.acip.gov.au/library/patentsexpuse .pdf
  • http://www.gtg.com.aufindex_general.asp?m enuid080.030
  • http://www.abc.net.au/4corners/content/200 3/2003081 l_patent/default.htm
  • http://www.smh.com.au/articles/ 192003/08/03 /1059849278757.html
  • http://www.abc.net.au/4corners/content/200 3/2003081 l_patent/int_jacobson.htm Holmes
  • http://www.med.govt.nz/buslt/int_prop/gene tic-material/cabinet/implications/ implications. pdf
  • http://www.med.govt.nz/buslt/int_prop/gene tic-material/cabinet/memo/memo.pdf
  • http://www.abc.net.au/4corners/content/200 3/2003081 l_patent/int_collins.htm
  • http://ott.od.nih.gov/res_tools.html
  • http://www.murdoch.edu.au/elaw/issues/v10 n4/rimmer104.html
  • http://www.acip.gov.au/library/patentsexpuse .PDF
  • http://www.aph.gov.au/hansard/senate/comm nee/57716. pdf
  • http://www.ipaustralia.gov.au/pdfs/news/ausf ta. pdf
  • http://www.oecd.org/clataoecd/48/12/24508 541.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.